Background
Cristina Adriana Popa
Buffering without benefit? The SODa-BIC study

This week, we will discuss SODaBIC trial: with ICU acidosis driven by multiple overlapping mechanisms, is bicarbonate infusion supported by robust evidence, or does it persist mainly out of habit rather than physiology?

Buffering without benefit? The SODa-BIC study
Background
Pallavi Prasad
Beyond Diabetic Kidney Disease: FIND-ing ...

FIND-CKD extends finerenone beyond diabetic kidney disease, showing slower eGFR decline and sustained albuminuria reduction in non-diabetic CKD. While the benefits are modest and cardiovascular effects remain uncertain, the trial opens the door to broader use of nsMRAs and raises important questions about combination therapy with SGLT2 inhibitors.

Beyond Diabetic Kidney Disease: FIND-ing Finerenone's Next Role
Background
Pallavi Prasad
On the right TRACK? Rivaroxaban to prevent ...

Can rivaroxaban improve cardiovascular outcomes in patients with advanced CKD.? Although vascular inflammation and thrombosis are at the heart of CV damage, anticoagulants have not previously shown benefits in CVD patients.

On the right TRACK? Rivaroxaban to prevent cardiovascular events in advanced CKD.
Background
Cristina Adriana Popa
Heir to the Throne? Obinutuzumab in the ...

This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy

Heir to the Throne? Obinutuzumab in the membranous nephropathy MAJESTY trial
Background
Pallavi Prasad
Is all kidney disease in Diabetics "Diabetic ...

In this edition of NephJC, we discuss the largest case series of kidney biopsies in patients with Diabetes.

Is all kidney disease in Diabetics "Diabetic Nephropathy"?

Cristina Popa

On the right TRACK? Rivaroxaban to prevent cardiovascular events in advanced CKD.

On the right TRACK? Rivaroxaban to prevent cardiovascular events in advanced CKD.

Can rivaroxaban improve cardiovascular outcomes in patients with advanced CKD.? Although vascular inflammation and thrombosis are at the heart of CV damage, anticoagulants have not previously shown benefits in CVD patients.

Making an IMPACT on BP: Why pills alone won't win the war

Making an IMPACT on BP: Why pills alone won't win the war

This week we will discuss whether a bundled, team-based hypertension intervention- featuring intensive BP targets, home monitoring, health coaching, and audit feedback- can overcome poverty, clinical inertia, and fragmented care to improve blood pressure control in low-income patients receiving care at federally qualified health centers.

Why-dralazine?! Population risk of drug induced vasculitis

Why-dralazine?! Population risk of drug induced vasculitis

This week, we will discuss why a large registry cohort was needed to move past decades of scattered case reports and clarify the true risk of hydralazine‑associated vasculitis. When rare events hide in noise, only scale can reveal the signal. Can population‑level data finally bring this paradox into focus?